Abstract We present the case of a 50‐year‐old male patient with metastatic clear cell renal cell carcinoma (mRCC) who developed a diffuse pulmonary opacification and lymphadenopathy during nivolumab maintenance therapy. This was diagnosed as presumed sarcoid granulomatous inflammatory reaction secondary to immunotherapy, which resolved with holding off therapy and the nivolumab was resumed
Renal cell carcinoma (RCC) is a highly vascular tumor, which may spread to the lungs and other organ...
Abstract Background Immune checkpoint inhibitors are new immunotherapy drugs globally used for many ...
Nivolumab is an immune checkpoint inhibitor that targets programmed death-1 on T cells and is design...
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antige...
Abstract Background Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are re...
Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasi...
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of n...
Background: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor i...
Immuno-oncology demonstrated substantial efficacy in cancer treatment. Immune-related adverse events...
We report on a 34-yr-old man with no medical history who presented in September 2014 with night swea...
We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian ma...
Introduction Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor di...
BackgroundMetastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with ge...
Background. Recent clinical trials proven the clinically significant efficacy and tolerability of ni...
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or...
Renal cell carcinoma (RCC) is a highly vascular tumor, which may spread to the lungs and other organ...
Abstract Background Immune checkpoint inhibitors are new immunotherapy drugs globally used for many ...
Nivolumab is an immune checkpoint inhibitor that targets programmed death-1 on T cells and is design...
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antige...
Abstract Background Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are re...
Immune checkpoint inhibitors (ICIs) have become pivotal in the treatment of lung cancer. An increasi...
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of n...
Background: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor i...
Immuno-oncology demonstrated substantial efficacy in cancer treatment. Immune-related adverse events...
We report on a 34-yr-old man with no medical history who presented in September 2014 with night swea...
We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian ma...
Introduction Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor di...
BackgroundMetastatic sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of RCC with ge...
Background. Recent clinical trials proven the clinically significant efficacy and tolerability of ni...
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or...
Renal cell carcinoma (RCC) is a highly vascular tumor, which may spread to the lungs and other organ...
Abstract Background Immune checkpoint inhibitors are new immunotherapy drugs globally used for many ...
Nivolumab is an immune checkpoint inhibitor that targets programmed death-1 on T cells and is design...